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 A b s t r a c t  
The present study mainly focuses on the novel floating in-situ gelling system for controlled delivery 
of ramipril. Ramipril has half-life of 2-4 hours and required dose is 10 mg day. Hence ramipril is a 
suitable candidate for sustained drug delivery system. A gastro retentive drug delivery system of 
ramipril was formulated to increase the resident time in stomach and to modulate the release 
behavior of the ramipril. Different formulations of ramipril were prepared by using different 
concentration of gelling polymer such as sodium alginate, gellan gum and calcium carbonate. 
Sodium citrate was used to prevent gelation outside the gastric environment. The formulation was 
studied for FT-IR study and DSC study to interpret the interaction between drug and polymer used. 
Formulation containing 0.50 % of sodium alginate, 0.50 % of gellan gum and 1.0 % of calcium 
carbonate showed the best gelling ability. For optimization of in-situ gelling system 32 full factorial 
design was employed to study the effect of independent variables, concentration of gellan gum (X1) 
and concentration of sodium alginate (X2) and dependent variables like viscosity, in vitro bouncy 
time, % drug release at 4 hr (Y3), % drug release at 6 hr (Y4) and % drug release at 8 hr (Y5). F8 
batch was selected as optimized batch based on buoyancy time (71 sec), viscosity 356.9cp, drug 
content 99.06 % and CPR 99.80 % at 12 hrs. The controlled release of ramipril from in-situ gelling 
system was observed and good fit to the Zero order and Korsmeyer Peppasmodel whichshows 
fickian diffusion (n=0.351) mechanism. Stability revealed that there was no noticeable change in 
characterizations. Thus, in-situ gel formulation is promising approach for gastroretentive controlled 
delivery of Ramipril. 
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. 
Introduction 
Ramipril is angiotensin converting enzyme (ACE) inhibitor 
antihypertensive class of medication [1]. ACE is a 
peptidyldipeptidase that catalyzes the conversion of angiotensin I 
to the vasoconstrictor substance, angiotensin II[2]. In hypertensive 
patients with normal renal function treated with ramipril alone for up 
to 56 weeks. The extent of absorption is at least 50-60% and is not 
significantly influenced by the presence of food in the GI tract[3]. 
Ramipril is a whitecrystalline or microcrystalline powder with 2-10 
mg/day dose, it is readily absorbed from the stomach, but 
undergoes extensive first-pass hepatic metabolism, with half-life of 
2to 4 hours[4-6]. Protein binding of ramipril is about 73-90 %[5].  
Due to short half-live it requires frequent dosing which lead to 
fluctuation in blood levels and decrease patient compliance. These 
attributes make ramipril agood candidate for controlled release 
dosage form. 
In-situ gel-forming preparations are „stimuli-responsive‰ polymeric 
drug-delivery systems that are conveniently delivered orally as a 
liquid, followed by a transition into a gel upon contact with the 
gastric uids in the stomach[7]. In-situ gelling formulations provide a 
novel idea of delivering drugs to patient as a liquid dosage form. It 
present control or sustain release of drug for the desire duration. 
Materials and Methods 
Materials 
Ramipril was obtained as gift sample from Ipca Laboratories Pvt. 
Ltd., Mumbai, India, Gellan Gum (Sisco Research Laboratories 
Pvt. Ltd., Mumbai, India), Sodium Alginate (SD fine Chem. 
Limited., Mumbai), Carrageenan (Himedia Laboratories Pvt. Ltd., 
Mumbai, India), Low Methoxy Pectin and High Methoxy Pectin 
(Krishna Pectines Pvt. Ltd., Sirsoli, India). All other reagents and 
chemicals used were of analytical grade. 
Methods 
Preliminary studies 
Four various concentrations of gellan gum were used, Among the 
four concentrations, 0.25%, 0.5% and 0.75% were selected for 
further studies because in this concentration gel was formed and 
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viscosities ranges were in acceptable limit. With 1% w/v 
concentration of gellan gum, very stiff gel was formed as well as 
viscosity was very high (Table 1) 
 
Table 1: Preliminary Studies 
Batch No. Polymer Concentration of 
polymer 
Viscosity of 
solutiona 
(cps) 
Gelling capacity 
T1 Gellan gum 0.25 % 163.4 μ 3.23 Gel is formed 
T2 Gellan gum 0.50 % 241.6 μ 2.98 Stiff gel is formed 
T3 Gellan gum 0.75 % 303.6 μ 3.21 Stiff gel is formed 
T4 Gellan gum 1.00 % 542.6 μ 4.32 Very Stiff gel is formed
T5 Sodium alginate 0.25 % 136.5 μ 3.24 Gel is formed 
T6 Sodium alginate 0.50 % 169.3 μ 3.78 Gel is formed 
T7 Sodium alginate 1.00 % 287.6 μ 4.24 Stiff gel is formed 
T8 Sodium alginate 1.50  % 393.6 μ 2.94 Stiff gel is formed 
T9 Low methoxy pectin 1.00 % 75.6 μ 2.17 Gel is not formed 
T10 Low methoxy pectin 4.00 % 92.3 μ 3.02 Gel is formed 
T11 High methoxy pectin 1.00 % 72.5 μ 2.42 Gel is not formed 
T12 High methoxy pectin 4.00 % 79.8 μ 3.41 Gel is not formed 
T13 Carrageenan 1.00 % 68.3 μ 2.97 Gel is not formed 
T14 Carrageenan 4 .00 % 83.4 μ 3.14 Gel is not formed 
*All the formulations contain 1% w/v calcium carbonate
 
Selection and optimization of calcium carbonate 
Calcium carbonate was used as gas forming agent. The calcium 
carbonate present in the formulation as insoluble dispersion is 
dissolved and releases carbon dioxide on reaction with acid, and 
the in-situ releases calcium ions resulting in formation of gel with 
floating characteristics.  It is established that formulations 
containing calcium carbonate produce a significantly stronger gel 
than those containing sodium bicarbonate. This is due to the 
internal ionotropic gelation effect of calcium on gellan [13,14]. 
Three various concentrations of calcium carbonate were taken. 
Among these three concentrations, with 1% calcium carbonate, 
buoyancy time was 42 sec; total floating duration and viscosity 
(174.6μ1.98) were in acceptable limit. So, 1% was selected for all 
the formulations. Increasing the calcium carbonate content in the 
formulation simultaneously increased the viscosity at all polymer 
concentrations studied (Table 2). 
Table 2:Optimization of calcium carbonate 
Polymera Calcium carbonate 
(%) 
Buoyancy timeb (Sec) Viscosityb (cp) Total floating durationa (h)
Sodium alginate 0.5 % 90 μ 10 171.4 μ 2.48 > 12 
Sodium alginate 1.0 % 42 μ 06 174.6 μ 1.98 >12 
Sodium alginate 1.5 % 63 μ 12 179.3 μ 2.75 >12 
Gellan gum 0.5 % 113 μ 11 246.2 μ 3.75 >12 
Gellan gum 1.0 % 52 μ 08 252.5 μ 2.38 >12 
Gellan gum 1.5 % 65 μ 07 261.31 μ 2.26 >12 
aIn concentration of 0.50 % w/v 
bAll the values are in mean μ SD (n=3)  
 
Optimization of concentration of sodium citrate 
The in-situ gelling formulation makes contact with an acidic 
medium and forms gel by cross linking with Ca++ ions and form a 
three dimensional gel network in acidic environment. Low level of 
cations present in the solution was sufficient to hold the molecular 
chains together so low level of sodium citrate is required to prevent 
gelation of in-situ gelling formulation before it comes contact with 
acidic medium[11]. At low concentration (0.15%), gel was formed 
with 0.1 N HCl, but after one day the formulation was converted to 
gel during storage. At medium concentration (0.20%), gelation was 
very good with 0.1 N HCl and the formulation was also stable 
(solution form) during storage. So, 0.20% was selected for final 
formulations. Same concentration was selected for gellan gum also 
(Table 3). 
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Table 3: Optimization of concentration of sodium citrate 
Polymersa Sodium citrate
(% w/v) 
Calcium 
carbonate 
(% w/v) 
Gelation in  0.1 N 
HClb 
After 1 day 
Sodium alginate 0.15 1.0 ++ Gel 
Sodium alginate 0.20 1.0 +++ Solution 
Sodium alginate 0.25 1.0 + Solution 
Gellan gum 0.15 1.0 +++ Gel 
Gellan gum 0.20 1.0 +++ Solution 
Gellan gum 0.25 1.0 + Solution 
a In concentration of 0.50 % w/v 
bGels after few minutes, dissolves rapidly;  
++ Gelation immediate remains for few hours;  
+++ Gelation immediate remains for extended period; 
++++ Gels after few minutes, remains for extended period. 
Preparation of floating in-situ gelling solution 
Polymer solution of different concentration was prepared in 
deionized water containing sodium citrate using magnetic stirrer. 
Low level of cations present in the solution is sufficient to hold the 
molecular chains together and inhibit hydration. A polymeric 
solution was heated at 60ÀC to uniform dispersion of polymer with 
stirring on magnetic stirrer. After cooling below 40ÀC, Drug is 
dissolve separately in deionized water, various concentrations of 
gas forming agent were added which is and dispersed well with 
continuous stirring. Finally drug and gas forming agent containing 
solution were added to the polymeric solution. The resulting in situ 
gel solution was finally stored in amber color narrow mouth bottles 
until further use. 
32 Full Factorial Designs 
A 32 full factorial design was applied to examine the combined 
effect of two formulation variables, each at 3 levels and the 
possible 9 combinations of ramipril in situ gel were prepared (Table 
2). The Concentration of gellan gum (X1) and the Concentration of 
sodium alginate (X2) were taken as independent variables. The 
viscosity, Buoyancy time (sec), cumulative percentage drug 
release at 4, 6 & 8 hrs were taken as dependent variables.[17] 
(Table 4, 5 & 6) 
 
Table 4: Factor and levels for 32 factorial design 
Variables  level Low (-1) Medium (0) High 
(+1) 
Concentration of 
gellan gum (X1) 
0.25 % 0.50 % 0.75 %
Concentration of 
sodium alginate (X2) 
0.00 % 0.25 % 0.50 %
 
 
 
 
 
Table 5: Coded value of factor in different batches of in-situ gelling 
formulations 
Batch No. X1 (A) X2(B)
R1 -1 -1
R2 0 -1
R3 1 -1
R4 -1 0 
R5 0 0 
R6 1 0 
R7 -1 1 
R8 0 1 
R9 1 1 
 
Table 6: Formulation table of various in-situ gelling formulations 
Batch 
No. 
Ramipril 
(mg/ml) 
X1(%) X2(
%) 
Calcium 
carbonate 
Sodium 
Citrate 
R1 2 0.25 0.00 1% 0.2 %
R2 2 0.50 0.00 1% 0.2 %
R3 2 0.75 0.00 1% 0.2 %
R4 2 0.25 0.25 1% 0.2 %
R5 2 0.50 0.25 1% 0.2 %
R6 2 0.75 0.25 1% 0.2 %
R7 2 0.25 0.50 1% 0.2 %
R8 2 0.50 0.50 1% 0.2 %
R9 2 0.75 0.50 1% 0.2 %
 
Measurement of melting point of ramipril 
Melting point was determined by taking small amount of ramipril in 
a capillary tube closed at one end.  The capillary tube was placed 
in an electrically operated digital melting point apparatus and the 
temperature at which the drug melts was recorded. This was 
performed thrice and average value was noted. 
FT-IR spectroscopy 
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The pure drug and drug with excipients were scanned separately. 
Potassium bromide was mixed with drug and/or polymer in 9:1 
ratio. Mixture of drug and/or polymer was compressed in palate 
using KBR press palate and the spectra were taken in FTIR 
spectrophotometer (Thermo Fisher Sci. Inc. USA Nicolat iS10). 
Differential scanning calorimetry (DSC) Study 
DSC analysis of pure drug and optimized formulation was 
performed with Shimadzu DSC 60 thermal analyser at the heating 
flow rates of 10ĈC per min between 50 and 300ĈC under static air 
using aluminium pans. 
Measurement of pH 
The pH of the prepared formulations was measured by digital pH 
meter (Systronics Ltd., Ahmedabad, India). 
Measurement of viscosity of in-situ gelling solution 
Viscosity of the samples was determined using a Brookfield digital 
viscometer (Model no: LVDV-III ULTRA Programmable 
Rheometer) with spindle S62. The sample temperature was 
controlled at 25μ1ÀC before the each measurement [8]. 
Measurement of in vitro buoyancy of in-situ gelling 
solution 
The in-vitro floating study was determined using USP dissolution 
apparatus II having 500 ml of 0.1 N HCl solution (pH 1.2). The 
medium temperature was maintained at 37μ2ĈC. 10 ml prepared in-
situ gel formulations was drawn up using disposable syringe and 
placed into the Petridish (4.5 cm internal diameter) and finally 
Petridis containing formulation was kept in the dissolution vessel 
containing medium without much disturbance. The time the 
formulation takes to emerge on the medium surface (floating lag 
time) was noted [9,10]. 
Measurement of in-vitro duration of floating of in-situ 
gelling solution 
The in vitro floating study was determined using USP dissolution 
apparatus II having 500 ml of 0.1 N HCl solution (pH 1.2). The 
medium temperature was maintained at 37μ2 ĈC. 10 ml prepared 
in-situ gel formulations was drawn up using disposable syringe and 
placed into the Petridis (4.5 cm internal diameter) and finally 
Petridis containing formulation was kept in the dissolution vessel 
containing medium without much disturbance. The time the 
formulation constantly float on the dissolution medium surface 
(duration of floating) was noted [9,10]. 
Measurement of in vitrogelation study 
The gelation study was carried out as described by Zhidong et al., 
with slight modification. The gelation cells were fabricating locally 
using Teflon. The cells were cylindrical reservoirs capable of 
holding 3 ml of the gelation solution (0.1 N HCl of pH 1.2). 500 øl 
transparent plastic cup was located at the bottom of cell within the 
cells to hold the gel sample in place after its formation. Then, 500 
øl of the preparation will be carefully placed into the cavity of the 
cup using micropipette, and 2 ml of the gelation solution (0.1 N HCl 
of pH 1.2) was added slowly in reservoir. Gelation will be observed 
by visual examination.  
The in vitro gelling capacity was graded in four categories on the 
basis of gelation time and time period for which the formed gel 
remains [8]. 
+ Gels after few minutes, dissolves rapidly 
++ Gelation immediate remains for few hours 
+++ Gelation immediate remains for extended period. 
++++ Gels after few minutes, remains for extended period. 
Measurement of drug content in formulation 
The drug content of the formulation will be determine by dissolving 
5 ml of in-situ gelling formulation in 40ml of methanol containing 50 
ml volumetric flask  followed by sonication for 30 min. Than volume 
is makeup to the mark.  The resulting solution will be filter and the 
drug content of solution will be measured at maximum absorbance 
at 222 nm using UV-Visible Spectrophotometer. 
Measurement of in vitro drug release 
The release of ramipril from the in-situ gel preparations was 
determined as described by Zatz and Woodford (1987) with some 
modification using USP dissolution test apparatus (USP XXIV) with 
a paddle stirrer at 50 rpm. This speed was slow enough to avoid 
the breaking of gelled formulation and will be maintaining with the 
mild agitation conditions believed to exist in vivo. The dissolution 
medium used will 500 ml of 0.1 N HCl (pH 1.2), and temperature 
were maintained at 37ĈC. 10 ml formulation was drawn up using 
disposable syringe. The syringe end was then place into the 
Petridis (4.5 mm internal diameter) and the syringe plunger 
depressed slowly to extrude 10 ml and finally Petridis containing 
formulation will keep in the dissolution vessel containing dissolution 
medium without much disturbance. At each time interval, a 
precisely measured sample of the dissolution medium will removes 
and replace with prewarmed (37ĈC) fresh dissolution medium. 
Absorbance of ramipril in withdrawn samples was measured using 
UV Visible Spectrophotometer (Shimadzu Corporation, Tokyo, 
Japan UV-1700 Pharma Spec) [11]. 
Stability study 
Prepared in situ gel formulation of ramipril was stored in a amber 
colored glass containers (well stoppered) for three months and the 
stability of the in situ gel suspension formulation of Ramipril was 
monitored up to 2 months at Controlled temperature (40 μ 2ĈC) and 
controlled humidity (75 μ 2 % RH) conditions. Periodically (initial, 
1and 2 months) samples were removed and evaluated for pH, 
viscosity, drug content and in vitro release[8,12]. 
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Results & Discussion 
Melting Point of Ramipril 
Melting point of Ramipril was determined by capillary tube method 
and it was found to be 109μ1.98 (n = 3). This value is similar as 
that of the literature citation 109 oC. 
FT-IR spectroscopy 
FT-IR studies were carried out for pure drug alone and final 
optimized formulation. FTIR spectrum of pure Ramipril was shown 
in the Figure 1.  Similarly FTIR spectra of optimized formulation 
were shown in Figures 1 and 2. Characteristic peaks were not 
affected and prominently observed in FTIR spectra given in Figures 
1 and 2. This indicates that there is no interaction between Ramipril 
and polymers and the drug was compatible with the formulation 
components. 
 
Figure 1: IR Spectrum of Ramipril 
 
 
Figure 2: IR Spectrum of optimized formulation 
 
Differential Scanning Calorimetry (DSC) Study 
Thermograph of Ramipril is shown in Figure 3. Melting transition of 
Ramipril was observed from 109.44ÀC (Onset) to 115.47ÀC 
(Endset). Sharpmelting transition of Ramipril was observed at 
112.06ÀC.  In the optimized formulation R8 (Figure 4) drug and 
excipients melting endotherm was observed from 108.95ÀC (Onset) 
to 114.98ÀC (Endset). Sharp melting transition of Ramipril in R8 
formulation was observed at 112.64ÀC. 
In case of optimized formulation drug peak is shifted to slightly 
lower temperature and decreases the intensity of peak which may 
be due to baseline shifting. There was no much difference in the 
melting point of the drug in all the thermographs. 
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Figure 3: DSC of pure ramipril 
 
Figure 4: DSC of optimized formulation-R8 
Experimental design 
32 full factorial design has been applied to optimize the formulation 
variables with basic requirement of understanding interaction of 
independent variables. Preliminary investigations of the process 
parameters revealed that factors like concentration of gellan gum 
(X1) and concentration of sodium alginate (X2) showed significant 
influence on viscosity (Y1), in vitro buoyancy time (Y2), amount of 
drug release in 4 hrs (Q4; Y3) and amount of drug release in 6 hrs 
(Q6; Y4) and amount of drug release in 8 hrs (Q8; Y5) of in situ gel 
formulations. Hence, they were utilized for further systematic 
studies. For all 9 batches, both the selected dependent variables 
(X1 and X2) showed a wide variation in viscosity, amount of drug 
dissolve and buoyancy time. The data clearly indicated strong 
influence of A and B on selected responses (Y1, Y2, Y3, Y4 and 
Y5). The polynomial equations can be used to draw conclusions 
after considering magnitude of coefficients and mathematical sign it 
conveys either positive or negative. Results for experimental 
design batches and its ANOVA were shown in table 7, 8, 9 and 
figure 5 ă 9. 
pH of in-situ gelling solutions 
Results of pH measurement of formulation R1 to R9 were 
described in Table 7. All the formulation has pH around neutral or 
slightly alkali. Maximum pH 7.4 was observed in R3 formulation 
and minimum pH 6.8 was observed in R8 formulations.
Table 7: Characterizations of in situ gelling formulations 
Batch 
No. 
pHa Viscositya 
(CP) 
In vitro buoyancy 
timea (Sec) 
Total floating 
time (h) 
Drug contenta 
(%) 
In vitro gelation 
studiesb 
R1 7.2μ0.4 118.4μ9.2 38μ4 >4 97.500μ 0.83 ++
R2 7.1μ0.3 195.6μ8.5 79μ5 >8 99.688μ 0.94 ++
R3 7.4μ0.3 261.6μ10.6 66μ3 > 12 98.542μ1.48 ++
R4 6.9μ0.4 195.5μ7.5 45μ3 > 10 96.667μ 1.18 ++
R5 7.0μ0.2 258.3μ5.8 56μ2 > 12 98.333μ 0.79 ++
R6 7.3μ0.3 345.4μ8.8 83μ6 > 12 98.750μ 0.63 +++
R7 6.8μ0.4 274.5μ7.4 58μ5 > 12 97.604μ1.48 +++
R8 7.2μ0.2 356.9μ6.3 71μ3 > 12 99.06μ 0.63 +++
R9 7.0μ0.4 496.5μ12.3 103μ4 > 12 97.292μ 1.91 ++++
a  All the values are in mean μ SD (n=3)  
b+ Gels after few minutes, dissolves rapidly,  
++ Gelation immediate, remains for few hours,   
+++ Gelation immediate, remains for extended period,  
++++ Gels after few minutes, remains for extended period. 
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Table 8:Summary of experimental design 
Batch code Factor 1 
Gellan Gum 
Factor 2  
Sodium 
Alginate 
Response 1 
Viscosity (cps) 
Response 2 
Buoyancy (Sec) 
Response 3
CPR at 4 hr 
Response 4 
CPR at 6 hr 
Response 5
CPR at 8 hr 
R1 -1 -1 118.4 38 95.24 99.86 100.05
R2 -1 0 195.6 79 85.13 99.77 99.89
R3 -1 1 261.6 66 72.5 86.28 99.53
R4 0 -1 195.5 45 83.13 94.19 99.48
R5 0 0 258.3 56 78.03 74.10 98.20
R6 0 1 345.4 83 67.67 83.98 93.96
R7 1 -1 274.5 58 69.41 81.25 91.05
R8 1 0 356.9 71 59.61 72.29 85.09
R9 1 1 496.5 103 55.89 67.94 81.11
 
Table 9: Polynomial coefficient of  all five responses 
Coefficient β0 β 1 β 2 β 11 β 22 β 12 
Y1 FM 259.08 92.05 87.52 19.70 15.22 14.42 
RM - - - - - - 
Y2 FM 63.307 8.17 18.5 - - - 
RM 63.307 - 18.5 - - - 
Y3 FM 77.54 -11.32 -8.62 -3.96 -0.93 2.30 
RM 77.27 -11.32 -8.62 -4.31 - 2.30 
Y4 FM 85.08 -10.73 -6.18 - - - 
RM - - - - - - 
Y5 FM 97.93 -7.036 -2.666 -4.78 -0.550 -2.355 
RM 97.77 -7.036 -2.663 -4.990 - -2.355 
 
 
Figure 5: Counter plot and 3D response plot of viscosity (Y1) with X1 and X2 
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Figure 6: Counter plot and 3D response plot of buoyancy (Y2) with X1 and X2 
 
Figure 7: Counter plot and 3D response plot of CPR at 4 hr (Y3) with X1 and X2 
 
Figure 8: Counter plot and 3D response plot of CPR at 6 hr (Y4) with X1 and X2 
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Figure 9: Counter plot and 3D response plot of CPR at 8 hr (Y5) with X1 and X2 
 
Viscosity of in-situ gelling solutions 
The rheological properties of the solutions are of importance in 
view of their proposed oral administration. In the selection of the 
concentration of gelling polymer a compromise is sought between 
a sufficiently high concentration for the formation of gels of 
satisfactory gel strength for use as a delivery vehicle, and a 
sufficiently low concentration to maintain an acceptable viscosity 
for ease of swallowing[15]. 
Results of viscosity formulation R1 to R9 were described in Table 
7. The solutions showed a marked increase in viscosity with 
increasing concentration of gellan and sodium alginate. 
In-vitro buoyancy of in-situ gelling solution 
The buoyancy of the prepared formulations was performed in 0.1 N 
HCl (pH 1.2). Results of in vitro buoyancy time of formulation R1 to 
R9 were described in Table 7. Formulations containing calcium 
carbonate demonstrated excellent floating ability, while 
formulations not containing this agent settled at the bottom of the 
medium. The calcium carbonate effervesced, releasing carbon 
dioxide and calcium ions. The released carbon dioxide is 
entrapped in the gel network, producing buoyant formulation; then, 
calcium ion reacted with gellan and produced a cross linked three 
dimensional gel network. 
In-vitro duration of floating of in-situ gelling solution 
The total floating time of the prepared formulations were performed 
in 0.1 N HC (pH 1.2). Results of in vitro total floating time of 
formulation R1 to R9 were described in Table 7. Reason for the 
less floating lag time of R1 formulation might be due to escape of 
CO2 air bubbles from the gelling network because of low 
concentration of polymer. R5 to R9 formulations have total floating 
lag time more than 12 hr. The possible reason behind that, 
combination of sodium alginate and gellan gum form stiff gelling 
system after contact with HCl. 
In-vitro gelation study 
Results of in vitro gelation are graded on arbitory scale from 
formulation R1 to R9 were described in table 7.The in-situ formed 
gel should preserve its integrity without dissolving or eroding for 
prolonged period to facilitate sustained release of drugs locally. R1 
to R5 formulations are forms gel immediately and remain for few 
hours. Low concentration of polymer is responsible for weak cross 
linked three dimensional network of gel, might be that is the reason 
for the degradation of gel after few hour. Formulations R6, R7 and 
R8 are forms gel immediately and remain for extended period. 
Formulation R9 form gel after few minutes and remains for 
extended period. Because of high concentration of gellan gum and 
sodium alginate it forms high stiff gel. 
Drug content 
Results of drug content of formulation R1 to R9 were described in 
Table 7. The solutions showed a percentage drug content from 
96.66% to 99.06 %. 
In-vitro drug release 
Dissolution profile of formulation of R1 to R9 is shown in Figure 10. 
The effect of polymer concentration on in vitro drug release from in-
situ gels is shown in Figure 5. A significant decrease in the rate 
and extent of drug release was observed with the increase in 
polymer concentration in in situ gels and is attributed to increase in 
the density of the polymer matrix and also an increase in the 
diffusional path length which the drug molecules have to 
traverse[16]. The release of drug from these gels was characterized 
by an initial phase of high release (burst effect). However, as 
gelation proceeds, the remaining drug was released at a slower 
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Conclusions 
This  study  reports  that  oral  administration  of  aqueous  
solutions  of  Ramipril containing gellan gum and sodium alginate 
results in formation of in situ gel at the stomach. From compatibility 
studies it was found that there was no interaction between the drug 
and polymer. The results of a 32 full factorial design revealed that 
the concentration of gellan gum sodium, alginate  and  
concentration  of calcium  chloride  significantly  affected  on  the  
dependent  variables like  viscosity (Y1), in vitro buoyancy (Y2),  
CPR at 4hr (Y3), CPR at 6hr (Y4) and CPR at 8hr (Y5).The 
optimized formulation R8 show in vitro sustains drug release up to 
12 hr. From the release kinetic it was concluded that R8 
formulation indicate zero order release as a best fit model. Stability 
revealed that there was no noticeable change in pH, viscosity, 
gelling capacity, buoyancy, total floating time, drug content and in 
vitro drug release profile. Thus, in situ gelling formulation is 
promising approach for gastroretentive controlled delivery of 
ramipril. 
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